Cipla to invest Rs 600 crore for R&D in FY15

04 Sep 2014 Evaluate

In a bid to implement research oriented projects, Pharma major Cipla is planning to invest about Rs 600 crore in research and development (R&D) in FY15. The company has undertaken a major expansion of its R&D Centre, with new buildings and facilities at Vikhroli in Mumbai. The company’s development and regulatory approval processes are on track. Currently, there are over 200 development projects underway indicating a robust pipeline.

The company has been granted many patents in the field of pharmaceuticals. The company’s R&D expenses increased from 5.1 per cent of its total revenue in FY13 to 5.4 per cent in FY14.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

 

Cipla Share Price

1497.00 -8.05 (-0.53%)
29-Dec-2025 13:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.45
Dr. Reddys Lab 1264.70
Cipla 1497.00
Zydus Lifesciences 903.70
Lupin 2084.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×